Skip to main content

A549 Transfection Reagent

The A549 cell line was established in 1972 by DJ Giad, et al. The original cells were derived from a cell culture of carcinomatous lung tissue of a 58 year old Caucasian male with lung cancer. Additional examination of the cells by M. Lieber, et. al. revealed the cells could synthesize lecithin with a higher percentage of denaturated fatty acid through the cytidine diphosphocholine pathway. The cells are hypotriploid human cells with 24% containing a modal chromosome number of 66. Findings have frequently found that the cells have a chromosomal count of  64,65,or 67. Typically, these cells act as in vitro cell models for type II pulmonary epithelial cell research examining drug metabolism within the cell. Often the A549 cells are used for research studies on respiratory illnesses such as, viral induced asthma infections, lung tissue damage resulting from asbestos exposure and smoker-related emphysema. 

 The development of knockdown systems and gene therapy treatments is possible through the use of the A549 transfection reagent developed by Altogen Biosystems. This transfection reagent enables the delivery of small interfering (siRNA), messenger RNA (mRNA), pDNA, and miRNA with an 80% efficiency rate. The A549 reagent has been pre-optimized to work efficiently in serum for consitent and easily reproducible studies. 

 A549 Transfection Reagent (Lung Carcinoma, CCL-185)
Labels:

Popular posts from this blog

Evodiamine Triggers Apoptosis in A549 Cells

Metadherin (MTDH) is a novel oncoprotein that promotes the survival and proliferation of lung cancer cells when over-expressed. In this study, researchers use staining assays and Western blotting analysis to investigate the anti-tumor effect of evodiamine in A549 cells, as well as its inhibitory effect on the MTDH pathway. Results show that evodiamine inhibits A549 cells by increasing the expression of proapoptotic protein Bax and therefore inducing apoptosis. Evodiamine consequently suppresses the proliferation of A549 cells through the inhibition of MTDH expression and induction of apoptosis. [ LINK ]
Post a Comment
Read more

Side Population Cells Present in A549 Cells

In the following study, researchers isolate and characterize side population (SP) cells that are present in the A549 cancer cell line. Fluorescence-activated cell sorting, assays, and a chemoresistance analysis were used to isolate and differentiate SP and non-SP (NSP) cells. Results show that SP cells account for 1.09% of live A549 cells and produced both SP and NSP cells. SP cells also exhibited improved invasive ability and had higher levels of chemoresistance compared to NSP cells in vitro.  Therefore, SP cells isolated from the A549 cell line exhibited more tumorigenicity, along with invasive ability and chemoresistance, than NSP cells. [ LINK ]
Post a Comment
Read more

Altogen Biosystems - Provider of Optimized Transfection Reagents

Altogen Biosystems is a well-known provider of transfection reagents and laboratory services world-wide for researchers in a variety of fields. Biology contract research services and products that are offered include assay development, reliable 28-day generation of stably-transfected cell lines, and _ laboratory services such as siRNA screening and ELISA assay development. For an A549 cell xenograftmodel , visit the Altogen Biosystems website.
Post a Comment
Read more